ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended				9 Months Ended	36 Months Ended	84 Months Ended
	Oct. 31, 2023 USD ($) right $ / shares	Feb. 28, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2026	Dec. 31, 2023	Jun. 30, 2024 USD ($)	Dec. 31, 2022 USD ($)
Licensing Arrangements [Line Items]
Payment to extinguish future royalty obligation					$ 295
Turning Point
Licensing Arrangements [Line Items]
Business combination, consideration transferred				$ 3,300
Total consideration				$ 4,100
Subsequent Event
Licensing Arrangements [Line Items]
Business combination, contingent value, number of rights received | right	1
Subsequent Event | Mirati Therapeutics
Licensing Arrangements [Line Items]
Share price (in usd per share) | $ / shares	$ 58.00
Business combination, consideration transferred	$ 4,800
Business combination, contingent value, share price (in dollars per share) | $ / shares	$ 12.00
Continent consideration liability										$ 1,000
Keytruda royalties | Forecast
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner									6.50%
Keytruda royalties | Forecast | Subsequent Event
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner								2.50%
Nimbus Therapuetics TYK2 Inhibitor
Licensing Arrangements [Line Items]
Proceeds from legal settlements						$ 40	$ 400
Contingent sales-based milestones		$ 2,000
Other			$ 400
LianBio Co. Ltd. | Mavacamten Rights | Subsequent Event
Licensing Arrangements [Line Items]
Payments to acquire rights	$ 350
Bristol-Myers Squibb | Keytruda royalties | Forecast | Subsequent Event
Licensing Arrangements [Line Items]
Payment and royalty allocation								75.00%
Ono | Keytruda royalties | Forecast | Subsequent Event
Licensing Arrangements [Line Items]
Payment and royalty allocation								25.00%
Immatics
Licensing Arrangements [Line Items]
Upfront payments						150
Contingent and regulatory milestone payments						770
Dragonfly
Licensing Arrangements [Line Items]
Upfront payments						$ 175
Nimbus Therapeutics
Licensing Arrangements [Line Items]
Upfront payments		$ 4,000
Nimbus Therapeutics | Nimbus Therapuetics TYK2 Inhibitor
Licensing Arrangements [Line Items]
Change in control proceeds						10.00%
Percentage of ownership acquired		100.00%
Mature products and other | Discontinued Operations, Held-for-sale
Licensing Arrangements [Line Items]
Assets held for sale											$ 172
Liabilities held for sale											20
Mature products and other | Cost of products sold
Licensing Arrangements [Line Items]
Asset impairment charges					$ 43
Mature products and other | LOTTE Corporation
Licensing Arrangements [Line Items]
Sales price											$ 159